Why the study?
Metabolic syndrome poses an additional risk for coronary artery disease and MACCE, motivating an investigation into the association between metabolic syndrome, its components, and MACCE after PCI in patients with ACS.
Does the presence of metabolic syndrome increase the risk of major adverse cardiac and cerebrovascular events in patients with acute coronary syndrome undergoing percutaneous coronary intervention?
Does the presence of metabolic syndrome increase the risk of major adverse cardiac and cerebrovascular events in patients with acute coronary syndrome undergoing percutaneous coronary intervention?
In patients with acute coronary syndrome undergoing PCI, the presence of metabolic syndrome, particularly driven by hypertension and impaired fasting glucose, is associated with a significantly increased risk of major adverse cardiac and cerebrovascular events.
No takes yet. Share an insight, caveat, or question.
MetS may signal higher post-PCI MACCE risk in ACS; leaves open whether targeting its components improves outcomes.
Hosseini et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: